LP
AMLX icon

Longaeva Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Longaeva Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200,000
Closed -$2.72M – 124
2025
Q3 		$2.72M Buy
+200,000
New +$1.88M 0.39% 44

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Longaeva Partners's AMLX Position: Q4 2025 in Review

Longaeva Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2025, closing a stake of 200,000 shares — an estimated $2.72M sold.

Longaeva Partners first reported a position in AMLX in Q3 2025 and held it in 1 quarter. The position peaked at $2.72M in Q3 2025. 179 funds tracked by Wall St. Rank hold AMLX as of Q4 2025.

  • Longaeva Partners reported no remaining Amylyx Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Longaeva Partners sold 200,000 Amylyx Pharmaceuticals shares in Q4 2025, an estimated $2.72M.
  • Longaeva Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Longaeva Partners's Amylyx Pharmaceuticals position peaked at $2.72M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2025.

Based on Longaeva Partners's 13F filing for Q4 2025, filed 17 Feb 2026.